Read more
Screening and early detection of prostate cancer refer to the diagnosis of the disease at an early stage, in the absence of local or distant signs or symptoms, when the individual would have no reason to look for medical assistance. This scenario confers a greater responsibility on the provider to uphold the doctrine primum non nocere (first of all, do no harm) than in the case of interventions on symptomatic conditions. Recent literature provoked significant controversy about the effectiveness of screening on reducing mortality from prostate cancer, and inflamed the debates about the risk/benefit of early diagnosis versus aggressive treatment, particularly due to the undefined behavior of most prostate malignancies, with the risk of treating many tumors that would not cause morbidity and certainly not result in death if they were not detected by screening (overdiagnosis and overtreatment). Against this backdrop of uncertainties, risks, and potential benefits, several international associations recently updated their guidelines for prostate cancer screening, emphasizing the importance of involving men in the decision whether to initiate or continue testing for prostate cancer.
About the author
Dr Frederico Romero graduated in Medicine, achieved the degree of Master of Surgery and the degree of Doctor of Philosophy at Federal University of Parana, completed his Residency in General Surgery and Urology at Santa Casa Medical School (Brazil), and a Research Fellowship in Endourology and Laparoscopy at the Johns Hopkins University (US).
